PDCD1 and esophageal adenocarcinoma: Meanwhile, the recently reported Phase 2 EDGE-Gastric assessed domvanalimab (anti-TIGIT antibody) and zimberelimab (anti-PD-1 antibody) with and without chemotherapy in 40 patients with first-line unresectable gastric, gastroesophageal junction or oesophageal adenocarcinoma.